Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NICE

- PMLiVE

UK’s NICE recommends Roche’s Evrysdi

The first oral therapy for the leading genetic cause of death among babies and young children will be available to 1,500 people in England after Roche signed a price-cutting deal

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

Woman on mobile phone

How femtech is changing the future of women’s health

The femtech industry has the potential to be the next stage of evolution in the open access movement. Taking on the role of a public library, which allows a wider...

Thrive Agency

Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence

Dr. Javier Mendoza, Gastroenterologist and Digital Health Expert, explores digital health in medicine and clinical research, natural language processing, the ethics surrounding AI, and his experience as a medical doctor...

Impetus Digital

- PMLiVE

NICE recommends Novartis’ Adakveo for sickle cell disease

The treatment for sickle cell disease is the first in more than 20 years

Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost

Lydia Zeller, CEO at Kiio, explores digital therapeutics, healthcare innovation, and Kiio’s innovative and personalized solutions for musculoskeletal (MSK) pain. She also shares her key leadership lessons and predictions for...

Impetus Digital

- PMLiVE

Why you should feel optimistic about the future of healthcare

It has been a difficult year to remain hopeful for those working in the healthcare industry, but there are some reasons to remain optimistic.

Say Communications

- PMLiVE

UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

The approval for the Novartis drug by the NHS gatekeeper could save 30,000 lives over 10 years

- PMLiVE

NICE recommends Novartis’ Rydapt for advanced SM treatment

The twice-daily, oral drug improves overall survival of people with the rare blood disorder

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

NICE approval for Lilly’s Verzenios is “fantastic news for thousands of women”

NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links